Clinical Trial Update: Dose Escalation Study of Cabozantinib for Advanced HCC Patients With Preserved Liver Function [Phase 2]

View source ↗

Summary

A Phase 2 dose-escalation trial of cabozantinib in advanced hepatocellular carcinoma with preserved liver function has completed, focusing on dosing and safety …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• cabozantinib (cabozantinib)

Snippet

Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Conditions: Hepatocellular Carcinoma (HCC), Second Line Treatment | Phase 2 | Status: COMPLETED